New combo therapy aims to control advanced liver cancer with vessel invasion
NCT ID NCT07466225
First seen Mar 17, 2026 · Last updated May 21, 2026 · Updated 12 times
Summary
This study tests whether adding a liver-directed chemotherapy infusion (HAIC) to a two-drug combination (lenvatinib and a PD-1 inhibitor) works better than the two drugs alone for people with advanced liver cancer that has invaded major blood vessels or bile ducts. About 150 adults will take part. The goal is to see if the triple therapy helps people live longer and keeps the cancer from growing, while checking for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Cancer Hospital
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.